What topics did the Phoenix Community discuss in May?
Phoenix members discussed a wide range of APOE4-relevant topics in May. Supplements and nutrition threads covered one-meal-a-day cognitive effects, coconut oil, optimal macro ratios for APOE4, ketosis tracking, modified citrus pectin, soluble fiber, microdosed semaglutide, testosterone therapy, and lithium microdosing. Biomarker discussions included cholesterol balance testing and hyper-absorb versus hyper-produce phenotyping. Research threads covered GLP-1 drugs for dementia prevention, SGLT2 inhibitors, creatine at 20g for brain energetics, HSV-1 links to Alzheimer risk, and APOE4 breakthroughs from the AAIC March 2025 conference on APOE and lipid biology.
Who is Professor Margit Burmeister and what did she discuss?
Professor Margit Burmeister is a Phoenix Founding Member who has spent decades researching the genetic roots of neurological and psychiatric disorders. Her expertise covers brain health, gene-environment interactions, and neurodegeneration. She is also an APOE2/4 carrier herself, giving her a uniquely personal perspective on APOE4 prevention. In a May Live Q&A with the Phoenix Community, she discussed DNA and genetics as they relate to APOE4 risk, how gene-environment interactions shape outcomes, and what her research reveals about neurodegeneration pathways.
What are monthly pods in the Phoenix Community?
Monthly pods group APOE4 carriers who share similar health profiles, including genetics, environment, habits, and goals, so members can swap protocols that are more likely to work for them specifically. The premise is that there is no one-size-fits-all answer in APOE4 prevention, but what works for people similar to you has a much higher chance of working for you too. May pods included the Lipid Lowering League for cholesterol, Resilience Circle for stress, Deep Sleep Guild for sleep, Quant Crew for biohacking, and Agility Alliance for sports.
Can GLP-1 drugs like semaglutide help prevent dementia in APOE4 carriers?
GLP-1 receptor agonists were a hot discussion topic in the Phoenix May update, with members exploring microdosed semaglutide and reviewing emerging evidence linking GLP-1 drugs to dementia prevention. Some members also discussed SGLT2 inhibitors and their potential Alzheimer prevention effects. These drugs were originally developed for diabetes and obesity but are now being studied for metabolic and neuroinflammatory effects on the brain. Phoenix did not make definitive claims but tracks the evolving research so APOE4 carriers can make informed decisions with their physicians.
